According to theWorld Health Organization, 37 million people living with HIV worldwide. More oftwo millionpeopleThey are infected each yearAnd is estimated to HIV treatment and careThey represent an expense of 22 million per year.
Una effective vaccine remains the best hope to end the epidemic.A combination of two long-acting drugs against HIV,rilpivirine and cabotegravirThat would be injected into theevery four to eight weeks have proven to be equally effectivein eliminating the virus that causes AIDS in the case of daily oral intake of three drugs against HIV.
An investigation is currently underclinical trials phase 2. In32 weeks, atviral suppression rates for patients receiving a dose every eight or four weeks were95 94% and%Respectively. Although extinction rates for patients who continued with the oral regimen of three drugs was 91%.
Paul Stoffels, Scientific director and president of the pharmaceuticalJohnson & JohnsonSaid that if these results are repeated in clinical trials of the last stage, the new treatmentIt could be available for the year 2020.
"Despite the advances in HIV treatment, the burden of treating patients with HIV remains high. Injectable formulations of long-acting can offer other HIV maintenance treatment options, "he said.
The new treatment could offer people living with HIV the option tochange the default regime of three drugs daily, for a system of "all-the -medicaments-of-action-extended-injected" that could keepviral suppression with only six or twelve administrations of each drug per year.
This is good news becauseEuropean CommissionHe decided to invest23 million to accelerateDevelopment of a vaccine against HIV,a project involvingthree Spanish teams: OInstitute for Research on AIDS ( IDIBAPS IrsiCaixa), the Hospital Clinic of BarcelonaeoInstitute of Health Carlos III of Madrid. The European Initiative for Vaccine against AIDS (EAVI2020) Is part of the program / research framework and horizon innovation 2020, brings together leading researchers from HIV public organizations and biotechnology companies throughout Europe, Australia, Canada and the United States. IDIBAPS and IrsiCaixa are members of the consortium that brings together scientists from 22 institutions.
The EAVI 2020 initiative brings together a multidisciplinary team of molecular biologists, immunologists, virologists, bio-technologists and physicians to provide the breadth of expertise required to move through the pre-clinical scale and production, the recent discoveries in the laboratory to the first clinical trials.